MRO Tracker · Pharma
A selection of recent US generic drug approvals disclosed by Indian companies, with the brand they copy, any exclusivity, and each company's running approval count. This is a curated log of notable approvals, not a complete list of every approval, and it grows as companies disclose new ones.
9selected approvals logged, Aug to Nov 2026
3with exclusivity or first to file status
599Aurobindo's cumulative ANDA approvals
458Zydus approvals to date
MRO View: The mix is moving toward harder products. Recent wins include a transdermal patch, a nasal spray, an eye drop and an oncology tablet, several with exclusivity. These products usually face fewer competitors than standard oral tablets.
Recent approvals
| Date | Company | Product | Reference brand | Status | Company total |
|---|---|---|---|---|---|
| 2 Nov 2026 | Lupin | Amifampridine tablets, 10 mg | Firdapse | First to file; eligible for 180 day shared exclusivity | Not disclosed |
| 5 Nov 2026 | Alembic Pharmaceuticals | Olopatadine ophthalmic solution 0.7% (OTC) | Pataday Once Daily Relief | Final approval | 248 |
| 31 Oct 2026 | Alembic Pharmaceuticals | Venetoclax tablets, 10, 50 and 100 mg | Venclexta | First applicant with Paragraph IV; may be eligible for 180 day exclusivity | 248 |
| 21 Oct 2026 | Zydus Lifesciences | Estradiol and levonorgestrel transdermal system | Climara Pro | Competitive Generic Therapy; 180 day exclusivity on launch | 458 |
| 17 Oct 2026 | Alembic Pharmaceuticals | Ciprofloxacin and dexamethasone otic suspension | Ciprodex | Final approval | 246 |
| 4 Oct 2026 | Aurobindo Pharma | Perampanel tablets, six strengths | Fycompa | Final approval | 599 |
| 4 Sep 2026 | Lupin | Modafinil tablets, 100 and 200 mg | Provigil | Final approval | Not disclosed |
| 20 Aug 2026 | Glenmark Pharmaceuticals | Fluticasone propionate nasal spray | Flonase | Final approval | Not disclosed |
| 17 Aug 2026 | Lupin | Pitolisant tablets, 4.45 and 17.8 mg | Wakix | Final approval | Not disclosed |
Cumulative approvals, as stated by each company
599
458
248
| Company | Approvals | Detail | As of |
|---|---|---|---|
| Aurobindo Pharma | 599 | 574 final, 25 tentative | Oct 2026 |
| Zydus Lifesciences | 458 | 516 ANDAs filed since FY04 | Oct 2026 |
| Alembic Pharmaceuticals | 248 | 229 final, 19 tentative | Nov 2026 |
Company totals include final and tentative approvals as each company reports them. Companies that did not state a running total are not ranked.
Need the numbers behind this tracker?
We profile US generic pipelines, exclusivity windows and competitor filings for pharma clients.
Get the monthly India tracker updateNew state data and new plant announcements in one short email, once a month.
One email a month. Reply to any email to unsubscribe. Privacy policy